| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID3924: Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia |
|
Medicine details |
|
| Medicine name | burosumab (Crysvita®) |
| Formulation | 10 mg, 20 mg, 30 mg solution for injection |
| Reference number | 4700 |
| Indication | Treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults |
| Company | Kyowa Kirin Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | ID3924: Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia |